The U.S. pharmaceutical industry has been kind to Ireland and its Taoiseach (Prime Minister) Enda Kenny this week. It has announced investments of more than Euro300 million ($400 million) in the country, which is starting to show early signs of economic recovery.
One after another, Pfizer's European subsidiaries are implementing the company's strategy of reducing its global headcount. In the past week, company employees in France, Germany and Belgium have been given the bad news.
The French genome engineering company Cellectis SA is to acquire the leading Swedish human embryonic stem cell firm Cellartis AB for around €30 million ($41.5 million) in a mix of cash and shares, in a move designed to produce a global leader in stem cell technologies for use as research tools and in the development of therapeutic products. The deal is expected to close around the end of October.
The U.K.' s National Institute for Clinical Excellence has put the brakes on Merck & Co.' s and partner Nycomed A/S' chronic obstructive pulmonary disease drug Daxas (roflumilast) for patients in the NHS in England and Wales, citing concerns over the high level of adverse incidents, uncertainties with the manufacturer's cost calculations and accuracy of trial evidence.